Ebola: The Ripple Effects (infographic)

For better or worse, Ebola is becoming old news. Aside from the initial case in Dallas that was transmitted to two nurses, there have been no more cases here in the U.S., and panicked predictions of a massive outbreak causing mayhem and catastrophe never materialized (much like public health experts said they would not – funny how that works).

The outbreak in West Africa is ongoing and continues to be a tragedy on a massive scale that is losing public interest. We previously posted an article by Mary Anne Mercer on lost opportunities and the weaknesses in the healthcare systems that the outbreak has laid bare. Now, the MPH@GW blog has kindly provided anĀ infographic on the outbreak and its collateral damage.

Ebola-Public-Health-Crisis-IG

Another Disease in the Crowd? Pneumonia back in the spotlight on World Pneumonia Day

Nearly every disease, cause, and social issue claims a calendar date for itself to raise awareness, from well-known causes such as HIV/AIDS and cancer to somewhat more obscure issues, such as parental alienation. Ā World Pneumonia Day, which was yesterday, is no exception.Ā  It, like many others, came amid general fanfare, advocacy, and, well, awareness, but it will undoubtedly step back into the crowd of causes competing for attention and funding.

But should it?

In this climate of fiscal austerity, foundations and organizations competing for an ever narrowing stream of donor funding.Ā  Times are tight, so each disease has to make its case, so to speak.Ā  Without a doubt, all of them are worth funding, but none of them will get the funding they need.Ā  The question, then, becomes one of priority: how do donors decide how to make their dollars count?

Pneumonia can make a compelling case for being at the front of the line.Ā  It is simultaneously the world’s number one killer of children under five and one of the world’s most preventable diseases.Ā  We have effective vaccines and proven interventions, including reducing indoor air pollution (which will also make the clean cookstoves people happy) and increasing breastfeeding during the first six months (which will make the breastfeeding advocates and MCNH people happy).

Unfortunately, the impact of pneumonia and the ease of treating it do not diminish the importance of other diseases.Ā  Many NTDs, for example, are extremely debilitating and only cost of a few cents to treat.Ā  Tuberculosis is re-emerging with a vengeance and frightening antibiotic resistance.Ā And recent shortfalls in contributions to the Global Fund endanger the gains we have made against HIV/AIDS, TB, and malaria.

So what is a cause to do?Ā Own its awareness day and get the word out, which is precisely what the major players, like the GAVI AllianceĀ and IVAC at Johns Hopkins, have done.Ā  Dr. Orin Levine is making his usual rounds.Ā  IVAC
has published a report card on the progress made by the 15 countries with the highest rates of childhood pneumonia, which examines their vaccination, treatment, and breastfeeding rates, in addition to progress in reducing pneumonia-related mortality.Ā  Extra points for getting their recent
vaccine drive in Nicaragua on PBS
, too.

I am no judge of which global health causes should be prioritized when it comes to funding – but then again, who among us is?Ā  All advocates can do is make their own individual cases.Ā  Let us hope that pneumonia can get the respect it deserves among the other worthy global health causes and not just go back to being another disease in the crowd after World Pneumonia Day.

The Greatest Thing You’ll Ever Learn: Drug-Resistant Tuberculosis on the Rise

On most days, tuberculosis only crosses the average American’s awareness radar when he or she is watching Moulin Rouge! for the fifth time. Even then, the sight of the courtesan Satine (played by Nicole Kidman) coughing up blood after singing about diamonds gives the impression that TB is the problem of sex workers living in elephants in 19th-century France. All of this changed in 2007, when Georgia lawyer Andrew Speaker snuck back into the U.S. through Canada after honeymooning in Europe – and being diagnosed with extensively-drug-resistant tuberculosis (XDR-TB).

As if regular TB were not bad enough, global health professionals are now grappling with the rising incidence of multi-drug-resistant (MDR-TB) and extensively-drug-resistant (XDR-TB) tuberculosis. MDR-TB is resistant at least to isoniazid and rifampicin, the two most powerful first-line antibiotics used to treat TB. It typically develops when patients being treated for fully sensitive TB stop their treatment course or do not follow it regularly (either because they feel better or forget to take their drugs, or because treatment supplies run out). When the treatment is interrupted before all of the bacteria are killed, the microbes develop resistance to the drugs. XDR-TB has all of this and more: it is also resistant to any fluoroquinolone and at least one of three injectable second-line drugs (capreomycin, kanamycin, and amikacin). If these drugs sound scary, it is because they are: most second-line drugs are less effective than isoniazid and rifampicin and can be moderately to highly toxic.

While the incidence of drug-resistant strains of TB is low for the moment, it is on the rise: a recent report by the WHO found that over two million people will contract some form of drug-resistant TB by 2015. The frequency of these infections is increasing fastest in India, China, and the former USSR. The WHO is asking countries to put their money where their mouths are and step up to fight the disease. “Commitments by some countries are too slow off the mark or simply stalled,” said Rifat Atun, director of strategy, performance and evaluation at the Global Fund. In the meantime, the greatest thing you’ll ever learn…is to finish your antibiotic course.